NDC 63083-6033-2 HUMAN OTC DRUG

Drug Status:  Active

Proprietary Name: Travel Immunization Detox 6033

Drug Overview

The NDC Code 63083-6033-2 is assigned to “Travel Immunization Detox 6033” (also known as: “Travel Immunization Detox”), a human otc drug labeled by “Professional Complementary Health Formulas”. The product's dosage form is liquid, and is administered via oral form.

Disclaimer

Do not rely on DataLabs to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of FDA-regulated products. We may limit or otherwise restrict your access to the API/WEB in line with our Terms of Service.

Drug Information
NDC Package Code	63083-6033-2
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Product NDC	63083-6033
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
11 Digit NDC Code	63083-6033-02
	It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format.
Proprietary Name	Travel Immunization Detox
	Also known as the trade name. It is the name of the product chosen by the labeler.
Non Proprietary Name	Travel Immunization Detox
	Sometimes called the generic name, this is usually the active ingredient(s) of the product.
Product Type Name	HUMAN OTC DRUG
	Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Proprietary Name Suffix	6033
	A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Labeler Name	Professional Complementary Health Formulas
	Name of Company corresponding to the labeler code segment of the ProductNDC.
Status	Active
	Possible status values: Active Active NDC Code Deprecated Deprecated NDC Code Unfinished (Unapproved) The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved.

Route & Dosage
Dosage Form Name	LIQUID
	The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Route Name	ORAL
	The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Pharmaceutical Classes	ACTIVELY ACQUIRED IMMUNITY [PE], ACTIVELY ACQUIRED IMMUNITY [PE], ACTIVELY ACQUIRED IMMUNITY [PE], ACTIVELY ACQUIRED IMMUNITY [PE], ACTIVELY ACQUIRED IMMUNITY [PE], ALLERGENS [CS], CELL-MEDIATED IMMUNITY [PE], HEPATITIS A VACCINES [CS], INACTIVATED CLOSTRIDIUM TETANI VACCINE [EPC], INACTIVATED HEPATITIS A VIRUS VACCINE [EPC], INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE [EPC], INACTIVATED POLIOVIRUS VACCINE [EPC], INCREASED HISTAMINE RELEASE [PE], INCREASED IGG PRODUCTION [PE], INSECT PROTEINS [CS], JAPANESE ENCEPHALITIS VACCINES [CS], LIVE ATTENUATED YELLOW FEVER VIRUS VACCINE [EPC], NON-STANDARDIZED INSECT ALLERGENIC EXTRACT [EPC], POLIOVIRUS VACCINES [CS], TETANUS TOXOID [CS], VACCINES, ATTENUATED [CS], VACCINES, INACTIVATED [CS], VACCINES, INACTIVATED [CS], VACCINES, INACTIVATED [CS], VACCINES, INACTIVATED [CS], YELLOW FEVER VACCINE [CS]
	These are the reported pharmaceutical class categories corresponding to the SubstanceNames listed above.

Substance & Strength
Substance Name	ANOPHELES QUADRIMACULATUS - 12 [hp_X]/59mL ARSENIC TRIOXIDE (Substance Adverse Reports) - 6 [hp_X]/59mL CHOLERA ENTEROTOXIN SUBUNIT B (Substance Adverse Reports) - 12 [hp_X]/59mL CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (Substance Adverse Reports) - 12 [hp_X]/59mL ECHINACEA ANGUSTIFOLIA WHOLE (Substance Adverse Reports) - 3 [hp_X]/59mL HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED) (Substance Adverse Reports) - 12 [hp_X]/59mL JAPANESE ENCEPHALITIS VIRUS STRAIN NAKAYAMA-NIH ANTIGEN (FORMALDEHYDE INACTIVATED) (Substance Adverse Reports) - 12 [hp_X]/59mL MELANDRIN (Substance Adverse Reports) - 30 [hp_X]/59mL MUMPS VIRUS (Substance Adverse Reports) - 12 [hp_X]/59mL OYSTER SHELL CALCIUM CARBONATE, CRUDE (Substance Adverse Reports) - 3 [hp_X]/59mL POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED) (Substance Adverse Reports) - 12 [hp_X]/59mL SALMONELLA ENTERICA ENTERICA SEROVAR TYPHI (Substance Adverse Reports) - 12 [hp_X]/59mL SILICON DIOXIDE (Substance Adverse Reports) - 3 [hp_X]/59mL SULFUR (Substance Adverse Reports) - 6 [hp_X]/59mL THUJA OCCIDENTALIS LEAF (Substance Adverse Reports) - 3 [hp_X]/59mL YELLOW FEVER VIRUS STRAIN 17D-204 LIVE ANTIGEN (Substance Adverse Reports) - 12 [hp_X]/59mL
	This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Drug Package Information
NDC Package Code	63083-6033-2
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Package Description	59 ML IN 1 BOTTLE, DROPPER (63083-6033-2)
	A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE.
Sample Package	N
	Defines whether given package serves sample purposes.
Package NDC Exclude Flag	N
	This indicates whether the package has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.
Package Start Marketing Date	19850815
	This is the date that the labeler indicates was the start of its marketing of the drug package.
Package End Marketing Date	N/S (NOT SPECIFIED)
	This is the date the package will no longer be available on the market. If a package is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Packages that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Packages with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

Product Application & Marketing Information
Product NDC	63083-6033
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Application Number	N/S (NOT SPECIFIED)
	This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Marketing Category Name	UNAPPROVED HOMEOPATHIC
	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Listing Record Certified Through	20271231
	This is the date when the listing record will expire if not updated or certified by the firm.
Product Marketing Start Date	19840815
	This is the date that the labeler indicates was the start of its marketing of the drug product.
Product Marketing End Date	N/S (NOT SPECIFIED)
	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Product NDC Exclude Flag	N
	This indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.

Tracking Information
Last Update Date	2026-01-09
	The date that a record was last updated or changed.